Tofersen (Qalsody)
Abstract
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Tofersen (Qalsody), 100 mg per 15 mL (6.7 mg/mL), solution for intrathecal injection. Indication: Qalsody (tofersen injection) is indicated for the treatment of adults with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene.
Fields of Study & Subjects
Amyotrophic Lateral Sclerosis Research
Neurogenetic and Muscular Disorders Research
Genetic Neurodegenerative Diseases
Publication details
- Journal / source
- Canadian Journal of Health Technologies
- Publisher
- Canadian Journal of Health Technologies, CADTH
- Volume
- 6
- Issue
- 3
- Publication date
- 27 March 2026